SHERIDAN, WYOMING - April 14, 2026 - Claret Capital Partners, a London-headquartered independent growth debt fund manager, has surpassed 200 portfolio companies and deployed more than €1.2 billion in growth capital since its 2013 founding, with deal activity accelerating sharply across the first quarter of 2026. The 200th-company milestone was reached with an investment in SIS Medical in January 2026, marking a tangible threshold for a firm that has built its franchise on non-dilutive debt instruments for expansion-stage SMEs. Operating across technology, life sciences, and climate tech, Claret targets revenue-generating businesses seeking capital without proportional equity dilution-a proposition that has gained institutional traction as venture equity markets have remained selective for growth-stage companies.
Business impact
Claret's Q1 2026 deal flow illustrates both the breadth of its sector coverage and its cross-border reach. On March 31, the firm extended a US$25 million follow-on investment in Paysend, a cross-border payments platform, deepening an existing relationship. On March 23, it provided €10 million in financing to Wellster Healthtech to support a European expansion program. On March 13, it committed €28 million to Cinclus Pharma-one of its larger single-company ticket sizes in the recent period. Earlier in March, the firm also entered a new investment in U.S.-based ACT LAB, extending its geographic footprint beyond its primarily European base. Together, these four transactions represent a concentrated capital deployment in under four weeks, signaling consistent fund utilization and active pipeline conversion.
Recent deal activity
The January 2026 pipeline was equally dense. Claret completed a €35 million investment in Holidu on January 14, directed toward growth and M&A at the vacation rental platform. On the same date, portfolio company Open Cosmos received a spectrum award from Liechtenstein, a development the firm highlighted for its implications for European space telecommunications infrastructure. In February, Neurent Medical-a Claret-backed medical device company-closed an oversubscribed €62.5 million Series C to accelerate commercial rollout of its NEUROMARK platform for chronic rhinitis treatment. In March, portfolio company GridBeyond attracted Samsung Ventures as a new shareholder in a €12 million equity round, a development that illustrates the downstream institutional interest Claret-backed businesses have been able to generate.
Sector positioning and market context
Claret is authorized and regulated by the Financial Conduct Authority and restricts its offering to professional clients and eligible counterparties. Its focus on debt-based growth capital addresses a structural gap between early-stage venture equity and late-stage private equity-a gap that widened as European venture valuations compressed in recent years. The firm was named Venture Debt Provider of the Year for the second consecutive year in November 2025, a recognition that positions it within the regulated institutional credit market rather than the less-structured end of alternative lending. Its stated sectoral alignment with technology, life sciences, and climate tech tracks closely with areas of concentrated European policy and institutional investor demand, providing its portfolio with sector tailwinds relevant to commercialization timelines and follow-on funding access.
Key facts:
- €1.2 billion+ deployed since 2013 inception
- 200th portfolio company (SIS Medical) reached in January 2026
- Q1 2026 investments: Paysend (US$25M follow-on), Wellster Healthtech (€10M), Cinclus Pharma (€28M), ACT LAB (U.S.)
- €35M invested in Holidu in January 2026 for growth and M&A
- Named Venture Debt Provider of the Year for second consecutive year, November 2025